AstraZeneca makes savings card for Arimidex users
WILMINGTON, Del. Anglo-Swedish drug maker AstraZeneca has created a savings card for users of one of its breast cancer drugs, AstraZeneca said Thursday.
The program, for women Arimidex (anastrozole), is designed to save patients up to $300. The program is tied to copays, so if a patient pays a $75 copay, AstraZeneca will cover $25, or $50 if the patient pays a $100 copay.
Arimidex treats hormone receptor-positive early breast cancer in postmenopausal women.
Pampers by Cynthia Rowley hitting Target shelves in July
CINCINNATI Pampers has teamed up with renowned fashion designer Cynthia Rowley to bring fashionable diapers to Target shoppers this summer.
Pampers by Cynthia Rowley will be available in 11 colorful styles — for boys and girls — beginning in mid July at Target stores and on Target.com. Pampers by Cynthia Rowley incorporate a beautiful look and feel — giving discerning parents high performance, value and choice of style. The diaper collection, which will be available in pastel designs, including madras, stripes and printed ruffles, is suited specifically to babies and toddlers and delivers the perfect blend of utility and aesthetics.
“Of course parents want the very best for their little ones,” said Jodi Allen, Procter & Gamble’s VP North America baby care. “We also know that sometimes it’s the little things — like how a baby is clothed — that can bring added joy to mom and dad. While performance always comes first, we know that design is also important to parents. We’re pleased to introduce the first diaper line that brings together the best of these two worlds.”
Eisai, SuperGen release data for Dacogen trial
DUBLIN, Calif. Japanese drug maker Eisai has released data on a late-stage clinical trial of a drug for leukemia, Eisai’s development partner said Wednesday.
SuperGen said that while the injectable drug Dacogen (decitabine) did not show statistically significant superiority in overall survival in elderly patients with acute myeloid leukemia compared over treatments given to patients in the control group, “a trend was evident.”
Based on findings, Eisai plans to submit a regulatory application to the Food and Drug Administration seeking approval for Dacogen as a treatment for elderly patients with AML. The drug already is approved to treat myelodysplastic syndromes.